蒽环类药物相关心脏毒性早期生物标志物研究进展

doi:10.11904/j.issn.1002-3070.2023.06.007

摘要/Abstract

摘要： 蒽环类药物是临床被广泛应用的抗肿瘤药物之一,其剂量相关心脏毒性会影响癌症患者的生活质量及生存率,故早期识别和预防蒽环类药物相关的心脏毒性显得尤为重要。本文就蒽环类药物相关心脏毒性早期生物标志物的研究进展作一综述。

Abstract: Anthracyclines are one of the widely used anti-tumor drugs in clinical practice.Its dose-related cardiotoxicity can affect the quality of life and survival rate of cancer patients,so early identification of anthracycline related cardiotoxicity is particularly important.This article provides a review of the research progress on early biomarkers of anthracycline related cardiotoxicity.

Key words: Anthracycline, Cardiotoxicity, Biomarker, Research progress

中图分类号:

R730.53

鲁亚杰, 王丽红. 蒽环类药物相关心脏毒性早期生物标志物研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 496-501.

LU Yajie, WANG Lihong. Advances in early biomarkers of anthracyclines related to cardiotoxicity[J]. Journal of Practical Oncology, 2023, 37(6): 496-501.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.06.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I6/496

参考文献

1 Sobczuk P,Czerwińska M,Kleibert M,et al.Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications[J].Heart Fail Rev,2022,27(1):295-319.
2 Simões R,Silva LM,Cruz A,et al.Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy:A narrative review[J].Biomed Pharmacother,2018,107:989-996.
3 Newby LK,Rodriguez I,Finkle J,et al.Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity:An educational collaboration among the cardiac safety research consortium,the duke clinical research institute,and the us food and drug administration[J].Am Heart J,2011,162(1):64-73.
4 Meessen J,Cardinale D,Ciceri F,et al.Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines:The icos-one trial[J].ESC Heart Fail,2020,7(4):1452-1466.
5 Demissei BG,Hubbard RA,Zhang L,et al.Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction[J].J Am Heart Assoc,2020,9(2):e014708.
6 Kirkham AA,Pituskin E,Thompson RB,et al.Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity:A secondary analysis of the manticore trial[J].Eur Heart J Cardiovasc Pharmacother,2022,8(2):130-139.
7 Kapoun AM,Liang F,O′Young G,et al.B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts:Fibrosis,myofibroblast conversion,proliferation,and inflammation[J].Circ Res,2004,94(4):453-461.
8 Ito T,Yoshimura M,Nakamura S,et al.Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes[J].Circulation,2003,107(6):807-810.
9 Xiao H,Wang X,Li S,et al.Advances in biomarkers for detecting early cancer treatment-related cardiac dysfunction[J].Front Cardiovasc Med,2021,8:753313.
10 Skovgaard D,Hasbak P,Kjaer A.BNP predicts chemotherapy-related cardiotoxicity and death:Comparison with gated equilibrium radionuclide ventriculography[J].PLoS One,2014,9(5):e96736.
11 Leerink JM,Verkleij SJ,Feijen EAM,et al.Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors:A systematic review[J].Heart,2019,105(3):210-216.
12 Tonry C,Russell-Hallinan A,McCune C,et al.Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction[J].Cardiovasc Res,2023,119(3):710-728.
13 Ndrepepa G.Myeloperoxidase-A bridge linking inflammation and oxidative stress with cardiovascular disease[J].Clin Chim Acta,2019,493:36-51.
14 Nettersheim FS,Schlüter JD,Kreuzberg W,et al.Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy[J].Basic Res Cardiol,2023,118(1):36-54.
15 Todorova VK,Hsu PC,Wei JY,et al.Biomarkers of inflammation,hypercoagulability and endothelial injury predict early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients[J].Am J Cancer Res,2020,10(9):2933-2945.
16 Badimon L,Peña E,Arderiu G,et al.C-reactive protein in atherothrombosis and angiogenesis[J].Front Immunol,2018,9:430-436.
17 Venugopal SK,Devaraj S,Jialal I.C-reactive protein decreases prostacyclin release from human aortic endothelial cells[J].Circulation,2003,108(14):1676-1678.
18 Venugopal SK,Devaraj S,Yuhanna I,et al.Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells[J].Circulation,2002,106(12):1439-1441.
19 Kuppa A,Tripathi H,Al-Darraji A,et al.C-reactive protein levels and risk of cardiovascular diseases:A two-sample bidirectional mendelian randomization study[J].Int J Mol Sci,2023,24(11):9129-9149.
20 Hasan D,Ismail Y,Al Tibi A,et al.Serum biomarkers for chemotherapy cardiotoxicity risk detection of breast cancer patients[J].Asian Pac J Cancer Prev,2021,22(10):3355-3363.
21 Pusceddu I,Dieplinger B,Mueller T.ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans[J].Clin Chim Acta,2019,495:493-500.
22 Seki K,Sanada S,Kudinova AY,et al.Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling[J].Circ Heart Fail,2009,2(6):684-691.
23 Sanada S,Hakuno D,Higgins LJ,et al.IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system[J].J Clin Invest,2007,117(6):1538-1549.
24 Veeraveedu PT,Sanada S,Okuda K,et al.Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress[J].Biochem Pharmacol,2017,138:73-80.
25 Huang G,Zhai J,Huang X,et al.Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy[J].Medicine(Baltimore),2018,97(38):e12447.
26 Chen C,Li J,Rossi L,et al.Prognostic role of serum soluble ST2 of advanced breast cancer patients:A retrospective cohort study[J].Transl Cancer Res,2023,12(8):2128-2137.
27 Joolharzadeh P,Rodriguez M,Zaghlol R,et al.Recent advances in serum biomarkers for risk stratification and patient management in cardio-oncology[J].Curr Cardiol Rep,2023,25(3):133-146.
28 Xu J,Kimball TR,Lorenz JN,et al.GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation[J].Circ Res,2006,98(3):342-350.
29 Kempf T,Eden M,Strelau J,et al.The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury[J].Circ Res,2006,98(3):351-360.
30 Dean M,Kim MJ,Dimauro S,et al.Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy-a prospective analysis[J].Cardiooncology,2023,9(1):23-32.
31 Putt M,Hahn VS,Januzzi JL,et al.Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin,taxanes,and trastuzumab[J].Clin Chem,2015,61(9):1164-1172.
32 Witman N,Zhou C,Häneke T,et al.Placental growth factor exerts a dual function for cardiomyogenesis and vasculogenesis during heart development[J].Nat Commun,2023,14(1):5435-5451.
33 Takeda Y,Uemura S,Iwama H,et al.Treatment with recombinant placental growth factor(PIGF)enhances both angiogenesis and arteriogenesis and improves survival after myocardial infarction[J].Circ J,2009,73(9):1674-1682.
34 Zhang Y,Cao C,Xin J,et al.Treatment with placental growth factor attenuates myocardial ischemia/reperfusion injury[J].PLoS One,2018,13(9):e0202772.
35 Accornero F,van Berlo JH,Benard MJ,et al.Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism[J].Circ Res,2011,109(3):272-280.
36 Kaya MK,Demir T,Bulut H,et al.Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization[J].Clin Exp Ophthalmol,2015,43(5):449-457.
37 Sharma UC,Pokharel S,van Brakel TJ,et al.Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J].Circulation,2004,110(19):3121-3128.
38 Al-Salam S,Kandhan K,Sudhadevi M,et al.Early doxorubicin myocardial injury:Inflammatory,oxidative stress,and apoptotic role of galectin-3[J].Int J Mol Sci,2022,23(20):12479.
39 Ky B,Putt M,Sawaya H,et al.Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin,taxanes,and trastuzumab[J].J Am Coll Cardiol,2014,63(8):809-816.
40 Vishnoi A,Rani S.miRNA biogenesis and regulation of diseases:An updated overview[J].Methods Mol Biol,2023,2595:1-12.
41 Frères P,Bouznad N,Servais L,et al.Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients[J].BMC Cancer,2018,18(1):102-110.
42 Lakhani HV,Pillai SS,Zehra M,et al.Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer[J].Sci Rep,2021,11(1):7954-7964.
43 Zhu JN,Fu YH,Hu ZQ,et al.Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity[J].Sci Rep,2017,7(1):11879.
44 Jing X,Yang J,Jiang L,et al.MicroRNA-29b regulates the mitochondria-dependent apoptotic pathway by targeting bax in doxorubicin cardiotoxicity[J].Cell Physiol Biochem,2018,48(2):692-704.
45 Han L,Ju A,Guo Y,et al.miR-126 inhibits vascular endothelial cell apoptosis in rats with coronary heart disease through PI3K/Akt pathway[J].Minerva Surg,2023,78(1):96-97.
46 Oatmen KE,Toro-Salazar OH,Hauser K,et al.Identification of a novel microRNA profile in pediatric patients with cancer treated with anthracycline chemotherapy[J].Am J Physiol Heart Circ Physiol,2018,315(5):1443-1452.
47 Horacek JM,Jebavy L,Vasatova M,et al.Glycogen phosphorylase BB as a potential marker of cardiac toxicity in patients treated with anthracyclines for acute leukemia[J].Bratisl Lek Listy,2013,114(12):708-710.
48 Finkelman BS,Putt M,Wang T,et al.Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer[J].J Am Coll Cardiol,2017,70(2):152-162.
49 Yu LR,Cao Z,Makhoul I,et al.Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients[J].Exp Biol Med(Maywood),2018,243(3):248-255.
50 Tian C,Yang Y,Bai B,et al.Potential of exosomes as diagnostic biomarkers and therapeutic carriers for doxorubicin-induced cardiotoxicity[J].Int J Biol Sci,2021,17(5):1328-1338.

[1]	鲁姣阳, 常进. 多发性骨髓瘤生物标志物研究进展[J]. 实用肿瘤学杂志, 2023, 37(1): 87-91.
[2]	李浩, 滕立臣. 外泌体环状RNA在前列腺癌中的研究现状[J]. 实用肿瘤学杂志, 2023, 37(1): 92-96.
[3]	吴蕊玥, 朱凯丽, 杨景茹, 令晓玲. HER2低表达乳腺癌的临床研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 570-575.
[4]	陈俊慧, 刘思雨, 贺长军. RUNX1在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 576-579.
[5]	刘佳, 杨道坤, 王燕平, 陈宝鑫, 王新伟, 申娇. PD-1抑制剂治疗肝细胞癌疗效相关生物标志物的研究现状[J]. 实用肿瘤学杂志, 2022, 36(4): 374-380.
[6]	赵浩然, 李满, 张玉宝. 肝细胞癌相关RNA结合蛋白研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 576-579.
[7]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.
[8]	冯羽昕(综述),朱春荣(审校). lncRNA-HEIH在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 87-90.
[9]	郭永东, 靳晶, 李利敏, 贺宇彤. 分化拮抗非蛋白质编码RNA(DANCR)在常见恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 69-73.
[10]	许健, 詹月萍, 蒋元烨, 曹勤. α-常春藤皂苷的抗肿瘤药理作用研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 553-556.
[11]	李素素, 周春祥. NKT细胞对肝癌免疫应答的双向调控作用[J]. 实用肿瘤学杂志, 2019, 33(6): 540-543.
[12]	胡琳, 沈佳. GDF-15在预测和监控表柔比星/环磷酰胺-多西他赛-曲妥珠单抗辅助治疗HER-2阳性乳腺癌患者产生心脏毒性中的作用[J]. 实用肿瘤学杂志, 2019, 33(4): 340-345.
[13]	赵金璐, 李国东刘明. 长链非编码RNA CCAT1与消化系统恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 367-370.
[14]	周婧, 综述, 李志高审校. Girdin蛋白与乳腺癌相关性的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 57-60.
[15]	刘冰梅, 夏丽杰, 刘忆梅, 杨晶. 皮肤鳞状细胞癌研究进展[J]. 实用肿瘤学杂志, 2015, 29(6): 545-548.